Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q3 EPS of ($0.38), $0.05 better than the analyst estimate of ($0.43). Revenue for the quarter came in at $56.26 million versus the consensus estimate of $58.83 million.

GUIDANCE:

Vanda Pharmaceuticals sees FY2025 revenue of $210-230 million, versus the consensus of $224.8 million.

For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.